Pfizer ended its six-month effort to buy AstraZeneca Monday following the London-based company's May 19 rejection of its last bid of 55 pounds a share in cash and stock. While British takeover law ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback